NIAID Site Search

NIH’s Advisory Committee to the Director (ACD) provides recommendations on program development, resource allocation, NIH administrative regulation, and other aspects of NIH policy.

Published: February 1, 2023

This document provides an overview of research and training programs opportunities for 2022-2023 available through the Division of Intramural Research.

Last Reviewed: November 3, 2022

This document provides an overview of research and training programs opportunities for 2019-2020 available through the Division of Intramural Research.

Last Reviewed: May 21, 2021

This document provides a summary of the meeting regarding universal influenza vaccines hosted by NIAID and FDA.

Last Reviewed: August 6, 2019

This document summarizes the cellular and molecular basis of the autoimmune attack in the AIRE-deficient lung and discusses the relevance.

Last Reviewed: April 8, 2022

This document outlines the agenda for the symposium on The Role of Cytokines in COVID-19 which occurred on December 1, 2020.

Last Reviewed: November 12, 2020

This document is about how all employees of RML are responsible for understanding the environmental and health impacts of their jobs.

Last Reviewed: August 6, 2019

This document provides information about the Biodefense Research Agenda for CDC Category A Agents in February 2002.

Last Reviewed: August 6, 2019

In the 34 years since the first observance of World AIDS Day, transformational progress has been made in the global fight against HIV/AIDS, yet challenges remain. Today, we at the National Institutes of Health reflect on the 40 million lives lost to the disease and renew our commitment to the research necessary to end the global pandemic. Innovative research led to the highly effective HIV

Published: December 1, 2022

This document provides a summary of the NIAID Expert Panel Review on Medical Chemical Defense Research on March 19, 2003.

Last Reviewed: March 19, 2003

Jordan Report: Accelerated Development of Vaccines (2002) from NIAID includes updates on vaccine research for specific infectious diseases.

Last Reviewed: December 31, 2002

A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with

Published: June 25, 2019

Jordan Report: Accelerated Development of Vaccines (2007) from NIAID includes updates on vaccine research for specific infectious diseases.

Last Reviewed: August 6, 2019

A large, long-term study of the impacts of COVID-19 on children has enrolled its first participant at the National Institutes of Health’s Clinical Center in Bethesda, Maryland. The study, which is supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will track up to 1,000 children and young adults who previously tested positive

Published: November 15, 2021

A woman with HIV who received a cord blood stem cell transplant to treat acute myeloid leukemia has had no detectable levels of HIV for 14 months despite cessation of antiretroviral therapy (ART), according to a presentation at today’s Conference on Retroviruses and Opportunistic Infections (CROI).

Published: February 15, 2022

A clinical trial to evaluate long-acting antiretroviral therapy (ART) for maintaining HIV suppression in people for whom adhering to conventional daily oral ART has been a challenge has begun at research sites across the United States. The study, called Long-Acting Therapy to Improve Treatment Success in Daily Life, or LATITUDE, will help determine whether a combination of two experimental

Published: May 9, 2019

NIH Opening Statement Senate LHHS FY 2019 Hearing: Prepared statement of Lawrence A. Tabak, D.D.S., PH.D., Principal Deputy Director, Office of the Director

Last Reviewed: August 16, 2018

Jordan Report: Accelerated Development of Vaccines (2012) from NIAID includes updates on vaccine research for specific infectious diseases.

Last Reviewed: December 31, 2012

With Gratitude to Dr. Hugh Auchincloss, and a Welcome to Dr. Sarah Read; Newcomer to NIH Funding? Attend the NIH Grants Process Primer Webinar; OLAW Annual Reports Are Due on December 1; Loan Repayment Program Application Deadline Is November 21

Published: October 16, 2024

A NIAID-sponsored Phase 2 clinical trial will evaluate potential new therapeutics for COVID-19.

Published: August 4, 2020

NIH strategic plan to develop medical countermeasures against possible terrorist attacks involving radioactive materials.

Last Reviewed: December 5, 2019

A fourth Phase 3 NIH clinical trial evaluating an investigational vaccine for coronavirus disease 2019 (COVID-19) has begun enrolling adult volunteers.

Published: September 23, 2020

Expert articles from Jordan Report: Accelerated Development of Vaccines (2012) from NIAID

Last Reviewed: December 31, 2012

A NIAID-supported Phase 3 clinical trial designed to evaluate if an investigational vaccine can prevent symptomatic COVID-19 in adults has begun.

Published: July 27, 2020

A NIAID-supported Phase 3 clinical trial evaluating an investigational COVID-19 vaccine called AZD1222 will enroll around 30,000 adult volunteers.

Published: August 31, 2020